In 2017, Life Length started a project on cancer research called ONCOCHECK. This project included a series of research studies on cancer that were being carried out over a period of two years as part of the EU research and innovation program HORIZON 2020. The objective of the ONCOCHECK project was to clinically validate telomere associated variables (TAVs) as biomarkers of different types of cancer.
The strong clinical results of the prostate cancer study have evolved into ProsTAV™, a new tool designed to improve the current prostate cancer diagnosis protocol by significantly reducing the number of unnecessary biopsies.
ProsTAV™ is a state-of-the-art prostate cancer risk-score biomarker developed by Life Length with our proprietary Telomere Analysis Technology® (TAT®) methodology. ProsTAV™, together with the current screening protocol, can save hundreds of thousands of men annually from undergoing unnecessary biopsies as well as enormous savings – hundreds of millions of dollars per year.
Before the test can be commercially available, we must now complete a series of regulatory and clinical milestones for which we require investment. We have launched our crowdfunding campaign with Crowdcube to give the opportunity to everyone who would like to help us move forward with this project. This campaign is an opportunity for everyone who wants to make an investment in a life sciences company with great technology. As well as the huge commercial opportunity, together we can make a social contribution towards the fight against prostate cancer; the most common cancer for men which affects over six million men worldwide and claims over 350,000 lives per year.
Learn more about our company, team and the opportunity by having a look at our pitch page. We sincerely welcome you for your support in our efforts!
Investments of this nature carry risks to your capital. Please Invest Aware.